Lincoln Pharmaceuticals Limited has provided a clarification to the National Stock Exchange of India (NSE) regarding its financial results for the quarter ended September 30, 2025. The company explained that the standalone and consolidated financial statements for the period, submitted on November 13, 2025, showed identical figures in the Profit and Loss statements. This similarity occurred because Lincoln Pharmaceuticals Limited's sole subsidiary had no financial transactions during the second quarter of the fiscal year 2026. Consequently, the consolidated financial results mirrored the standalone results as there were no additional financial activities at the subsidiary level to report. The clarification was issued in response to an email from the NSE dated January 7, 2026, concerning the format of the submitted financial results.
